BioAge Labs (BIOA) Faces Securities Class Action On Behalf Of IPO Investors After Discontinuing Weight-Loss Drug Trial- Hagens Berman
(NASDAQ:BIOA), SAN FRANCISCO, Jan. 20, 2025 (GLOBE NEWSWIRE) — BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who allege the company misled investors about the safety and prospects of a key drug candidate before its initial public offering last September. Hagens Berman urges investors who […]